Nature of Business (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) segment	Sep. 30, 2021 USD ($)	Nov. 03, 2022 USD ($)	Aug. 05, 2022 USD ($)	Dec. 31, 2021 USD ($)	Aug. 13, 2021 USD ($)	Dec. 31, 2020 USD ($)
Nature of business:
Number of operating segments | segment			2
Accumulated deficit	$ (215,809,891)		$ (215,809,891)				$ (205,765,107)
Net loss	(3,309,003)	$ (3,587,551)	(10,044,784)	$ (7,847,097)
Net cash used in operating activities			(9,021,880)	(8,684,266)
Cash and cash equivalents	16,865,642	$ 28,867,487	16,865,642	28,867,487			26,043,897		$ 18,676,663
Net decrease in cash			9,178,255	(10,190,824)
DO NOT USE Cash and cash equivalents, increase (decrease)			$ (9,178,255)	$ 10,190,824
Percentage change in cash and cash equivalent			(35.00%)
Working capital	7,827,078		$ 7,827,078				20,278,345
Working capital increase, decrease			$ (12,451,267)
Working capital increase (decrease) as a percent			(61.00%)
Government grant funding	130,742		$ 130,742				$ 138,889
Common Stock, Value, Subscriptions						$ 26,700,000		$ 30,000,000
Subsequent Event [Member]
Nature of business:
Common Stock, Value, Subscriptions					$ 26,700,000
CiVax
Nature of business:
Revenue from collaborative arrangement			$ 1,500,000
Term (in years)			two years
NIH
Nature of business:
Government grant funding	$ 800,000		$ 800,000
NIAID | Contract revenue
Nature of business:
Revenue from collaborative arrangement			$ 700,000
Term (in years)			five years
DTRA | Contract revenue
Nature of business:
Revenue from collaborative arrangement			$ 600,000
Term (in years)			three years